Nike Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Nike Inc trades at $34.71 (market cap $51.60B), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Nike Inc is the larger of the two by market cap, and Nike Inc pays a 4.72% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| NKE | RVMD | |
|---|---|---|
Market Cap | $51.60B | $40.32B |
Volume | 43,506,062 | 4,855,734 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $221.15 |
52-Week Low | $33.87 | $47.50 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $54.30B | $37.02B |
Dividend Yield | 4.72% | — |
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $34.74, up 1.11% with bearish technical signals despite recent earnings beats. The company faces revenue pressure with FY2025 sales declining to $46.31B and net margin compressing to 6.74%. Analyst consensus remains positive with a $36.98 price target, though technical indicators show 16 sell signals against 2 buy signals. Recent news highlights challenges in China and EMEA markets while emphasizing Nike's strong brand positioning.
Nike's investment case balances strong brand equity against near-term operational headwinds. The stock offers value at 16.62 P/E with 21.56% ROE, but investors face risks from sluggish consumer demand and margin pressure. The upcoming Q4 2026 earnings on June 30 will be critical for confirming turnaround progress.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →